TrialX
Image

A Blind Self Controlled Multicenter Clinical Trial on the Effectiveness and Safety of Noninvasive Flow Reserve Score Analysis Software for Coronary Angiography

A Blind Self Controlled Multicenter Clinical Trial on the Effectiveness and Safety of Noninvasive Flow Reserve Score Analysis Software for Coronary Angiography

Recruiting
18-75 years
All
Phase N/A

Overview

This is a blind evaluation, self-control, multicenter clinical trial. 340 patients who need selective operation to evaluate the function of coronary artery were selected and measured with ctffr and FFR. The data of the experimental group was defined as: FFR value at the distal end of stenosis was obtained by calculating the original DICOM data of coronary CT angiography (CCTA) before operation with the non-invasive blood flow reserve analysis software of Hangzhou ArteryFlow Technology Co., Ltd. The gold standard group data is the clinical measured FFR (clinical gold standard) at the stenosis lesions. It is defined that when the coronary artery reaches the maximum congestion state, the pressure value at the distal end of the stenosis lesions is accurately measured by the guide wire with a pressure sensor, and the ratio value with the coronary mouth pressure is the FFR. By comparing the data of the experimental group and the data of the gold standard group, the effectiveness and safety of the devices in the experimental group were evaluated.

Eligibility

Inclusion Criteria:

  1. The age is 18-75 years old (including 18 and 75 years old);
  2. Subjects with clinical need and consent for coronary angiography;
  3. Can provide the results of coronary CT angiography within 60 days or agree to carry out coronary CT angiography;
  4. The subjects knew about the experiment and signed the informed consent voluntarily.

Exclusion Criteria:

  1. Patients who have had percutaneous coronary intervention (PCI);
  2. Patients who had CABG;
  3. Acute coronary syndrome, such as acute ST segment elevation;
  4. Severe tachycardia or arrhythmia;
  5. Patients with severe hepatorenal insufficiency;
  6. Patients with congenital heart disease, implanted pacemaker or defibrillator, artificial heart valve;
  7. Failure to perform invasive FFR examination or obtain FFR value due to various reasons;
  8. Allergic to - blockers, nitrates and adenosine, sick sinus syndrome, long QT syndrome, severe hypotension, severe asthma, severe COPD or COPD;
  9. Persistent or significant clinical instability, including acute chest pain (sudden onset), cardiogenic shock, blood pressure instability (systolic blood pressure < 90mmHg) and severe congestive heart failure (according to the heart classification of the New York Heart Association, grade III or IV of cardiac function) or acute pulmonary edema;
  10. The CTA images of coronary artery showed that the stenosis rate was less than 30% or more than 90%, or the diameter of diseased segment was less than 2.0mm;
  11. Ct-ffr can not be calculated because of the quality of CTA image;
  12. Known pregnant and lactating women;
  13. Having participated in other clinical trials within 3 months;
  14. Other situations that the researchers judged were not suitable for inclusion.

Study details
    Coronary heart disease

NCT04426396

Second Affiliated Hospital, School of Medicine, Zhejiang University

16 February 2024

Step 1 Get in touch with the nearest study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team


Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.